These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 20061962)
1. Psychometric evaluation of a Patient-Rated Most Troubling Symptom Scale for Depression: findings from a secondary analysis of a clinical trial. Pandina GJ; Garibaldi GM; Revicki DA; Kleinman L; Turkoz I; Kujawa MJ; Mahmoud RA Int Clin Psychopharmacol; 2010 Mar; 25(2):51-9. PubMed ID: 20061962 [TBL] [Abstract][Full Text] [Related]
2. Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial. Pandina GJ; Revicki DA; Kleinman L; Turkoz I; Wu JH; Kujawa MJ; Mahmoud R; Gharabawi GM J Affect Disord; 2009 Nov; 118(1-3):139-46. PubMed ID: 19321206 [TBL] [Abstract][Full Text] [Related]
3. Psychometric evaluation of a patient-rated troubling symptom scale for generalized anxiety disorder clinical trials. Pandina GJ; Revicki DA; Kleinman L; Turkoz I; Wu J; Mahmoud R; Gharabawi GM Psychopharmacol Bull; 2008; 41(3):68-90. PubMed ID: 18779777 [TBL] [Abstract][Full Text] [Related]
4. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep. Endicott J; Paulsson B; Gustafsson U; Schiöler H; Hassan M J Affect Disord; 2008 Dec; 111(2-3):306-19. PubMed ID: 18774180 [TBL] [Abstract][Full Text] [Related]
5. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901 [TBL] [Abstract][Full Text] [Related]
6. A comparative meta-analysis of Clinical Global Impressions change in antidepressant trials. Spielmans GI; McFall JP J Nerv Ment Dis; 2006 Nov; 194(11):845-52. PubMed ID: 17102709 [TBL] [Abstract][Full Text] [Related]
7. Development of Depression Profile: a new psychometric instrument to selectively evaluate depressive symptoms based on the neurocircuitry theory. Faludi G; Gonda X; Kliment E; Bekes V; Mészáros V; Oláh A Neuropsychopharmacol Hung; 2010 Jun; 12(2):337-45. PubMed ID: 20606243 [TBL] [Abstract][Full Text] [Related]
8. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. Alpert JE; Franznick DA; Hollander SB; Fava M J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591 [TBL] [Abstract][Full Text] [Related]
9. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. Demyttenaere K; Andersen HF; Reines EH Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937 [TBL] [Abstract][Full Text] [Related]
10. Effects of endogenicity and severity on consistency of standard depression rating scales. White J; White K; Razani J J Clin Psychiatry; 1984 Jun; 45(6):260-1. PubMed ID: 6725218 [TBL] [Abstract][Full Text] [Related]
11. Validation of the sleep impact scale in patients with major depressive disorder and insomnia. Lasch K; Joish VN; Zhu Y; Rosa K; Qiu C; Crawford B Curr Med Res Opin; 2009 Jul; 25(7):1699-710. PubMed ID: 19505198 [TBL] [Abstract][Full Text] [Related]
12. Using longitudinal data from a clinical trial in depression to assess the reliability of its outcome scales. Laenen A; Alonso A; Molenberghs G; Vangeneugden T; Mallinckrodt CH J Psychiatr Res; 2009 Apr; 43(7):730-8. PubMed ID: 18986657 [TBL] [Abstract][Full Text] [Related]
13. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Pandina GJ; Canuso CM; Turkoz I; Kujawa M; Mahmoud RA Psychopharmacol Bull; 2007; 40(3):41-57. PubMed ID: 18007568 [TBL] [Abstract][Full Text] [Related]
14. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710 [TBL] [Abstract][Full Text] [Related]
15. The Bipolar Depression Rating Scale (BDRS): its development, validation and utility. Berk M; Malhi GS; Cahill C; Carman AC; Hadzi-Pavlovic D; Hawkins MT; Tohen M; Mitchell PB Bipolar Disord; 2007 Sep; 9(6):571-9. PubMed ID: 17845271 [TBL] [Abstract][Full Text] [Related]
16. Adjunctive bright light in non-seasonal major depression: results from clinician-rated depression scales. Martiny K; Lunde M; Undén M; Dam H; Bech P Acta Psychiatr Scand; 2005 Aug; 112(2):117-25. PubMed ID: 15992393 [TBL] [Abstract][Full Text] [Related]
17. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467 [TBL] [Abstract][Full Text] [Related]
18. Depression and somatic symptoms scale: a new scale with both depression and somatic symptoms emphasized. Hung CI; Weng LJ; Su YJ; Liu CY Psychiatry Clin Neurosci; 2006 Dec; 60(6):700-8. PubMed ID: 17109704 [TBL] [Abstract][Full Text] [Related]